Introduction
============

Growing concern over the sharp increase in the prevalence of thyroid cancer in past decades, particularly papillary thyroid carcinoma (PTC), has prompted investigators to explore the molecular underpinnings of the disease, leading to the identification of BRAFV600E and RAS mutations, as valid therapeutic targets.[@b1-cmar-11-2059]--[@b3-cmar-11-2059] Recently, the Encyclopedia of DNA Elements project, which was designed to discover and characterize novel RNAs transcripts, has revealed that a large amount of primary or processed protein-coding and noncoding transcripts, including thousands of long noncoding RNAs (lncRNAs), are predominantly implicated in the human genome.[@b4-cmar-11-2059],[@b5-cmar-11-2059] Notably, increasing studies have demonstrated that deregulated expression of lncRNAs was significantly involved in the pathogenesis of multiple types of cancer.[@b6-cmar-11-2059],[@b7-cmar-11-2059]

The lncRNAs are a new class of nonprotein transcripts with over 200 bases in length.[@b8-cmar-11-2059] Emerging evidence has indicated that the *lncRNA H19*, frequently deregulated in almost all tumor types tested, acted as a critical contributor to both cancer initiation and progression.[@b9-cmar-11-2059] Li et al reported that overexpression of *lncRNA H19* enhances carcinogenesis and metastasis of gastric cancer.[@b10-cmar-11-2059] Guan et al reported that overexpression of *lncRNA H19*/miR-675 promotes tumorigenesis in head and neck squamous cell carcinoma.[@b11-cmar-11-2059] A study by Shi et al demonstrated that *lncRNA H19* predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration, and epithelial-mesenchymal transition (EMT) in melanoma cells.[@b12-cmar-11-2059] Moreover, preclinical and clinical studies have highlighted the therapeutic potential against *lncRNA H19*. For instance, Zhao et al showed that downregulation of *lncRNA H19* inhibits migration and invasion of human osteosarcoma through the NF-κB pathway.[@b13-cmar-11-2059]

Despite enormous breakthroughs in the understanding of the role of *lncRNA H19* in multiple types of tumor progression, the exact role and function of *lncRNA H19* in human PTC remain under-investigated. A major mechanism through which BRAF mutation might contribute to primary PTC progression is through induction of EMT.[@b14-cmar-11-2059],[@b15-cmar-11-2059] Specifically, the Snail/*E-cadherin* axis has been demonstrated as a pathway dysregulated by BRAF, leading to EMT.[@b16-cmar-11-2059] The possibility that *lncRNA H19* can regulate EMT program is an attractive option to explore. In this study, we identified that the *lncRNA H19* was significantly increased in PTC tissues and associated with classic EMT markers in PTCs, suggesting that *lncRNA H19* may be required for human PTC tumorigenesis and development.

Patients and methods
====================

Patients and clinical tissue samples
------------------------------------

Written informed consents were received from all patients before enrollment, and this study was approved by the Ethics Committee of Shantou University Medical Hospital. Fifty-eight PTC tissue samples and their paired paracancerous tissue samples were obtained from patients (age range: 27--72 years; 16 males and 42 females), who were first diagnosed between June 2016 to December 2017 at the First Affiliated Hospital of Shantou University Medical Hospital for quantitative real-time (qRT)-PCR analyses and paraffin-embedded pathological investigation. All medical histories of the patients were well-documented according to the eighth edition of the American Joint Committee on Cancer TNM system.[@b17-cmar-11-2059]

Cell lines and cell culture
---------------------------

The human PTC cell line B-CPAP was purchased from the Chinese Academy of Sciences (Beijing, China). This cell line was established from the tumor tissue of a woman aged 72 years with metastatic PTC in 1992.[@b18-cmar-11-2059] Cells were cultured in RPMI-1640 medium, containing 10% FBS, 100 U/mL penicillin, and 100 mg/mL streptomycin (all from Thermo Fisher Scientific, Waltham, MA, USA) in a 5% CO~2~ incubator at 37°C.

RNA purification and RT-PCR analysis
------------------------------------

All obtained tissues during surgery were immediately stored in liquid nitrogen prior to use. Total RNA (1 µg) was isolated from tissues or cells using TRIzol (Thermo Fisher Scientific) following the manufacturer's instructions and stored at −80°C. Reverse transcription was performed using a Prime-Script™ RT reagent kit (Takara Bio Inc., Shiga Prefecture, Japan) according to the manufacturer's instructions. To detect mRNA expression, qRT-PCR was performed with an SYBR Select Master Mix (Thermo Fisher Scientific) and a CFX96 RT-PCR Detection System (Bio-Rad Laboratories Inc., Hercules, CA, USA). To normalize the amount of mRNA in each sample, GAPDH was used. Primer sequences used in RT-PCR are listed in [Table S1](#SD3-cmar-11-2059){ref-type="supplementary-material"}.

Small interfering RNAs (siRNAs) and transfection
------------------------------------------------

The siRNAs were purchased from Suzhou GenePharma Co., Ltd. (Suzhou, China). The siRNAs are shown in [Table S2](#SD4-cmar-11-2059){ref-type="supplementary-material"}. Cells were transfected using Lipofectamine 3000 (Life Technologies, Carlsbad, CA, USA). A total of 1×10^6^ B-CPAP cells were inoculated into each well of a 6-well culture plate. The next day, 75 pmol of siRNA was combined with 3.75 µL of Lipofectamine 3000 (Life Technologies) by strictly following the manufacturer's instructions.

Western blot assay
------------------

Cells were lysed in RIPA buffer (Cell Signaling Technology, Danvers, MA, USA) with protease inhibitors. The extracted protein sample was measured using the BCA protein assay and was stored at −80°C until required for use. The 30 µg protein sample was separated by 8% SDS-PAGE and transferred onto a PVDF membrane (EMD Millipore, Billerica, MA, USA). After transferring, the membrane was blocked in 5% nonfat milk and then incubated with primary antibodies at 4°C overnight. The antibodies are shown in [Table S3](#SD5-cmar-11-2059){ref-type="supplementary-material"}. The next day, the membrane was incubated with secondary antibodies and subjected to electrochemiluminescence detection (Applygen Technologies, Inc., Beijing, China).

Wound healing assay
-------------------

Thirty minutes before the application of injury lines, B-CPAP cells were treated with Mitomycin C (25 mg/mL) (Beyotime Institute of Biotechnology, Jiangsu, China). Injury line was made with a 2-mm wide tip separated on cells plated in culture dishes at 90% confluency. After washing with PBS, cells could migrate in complete medium and photographs were taken (×40) after 48 hours. An average of five random widths of each injury line was measured for quantitation.

Transwell invasion assays
-------------------------

Cell culture inserts (8 M pore size; BD, Franklin Lakes, NJ, USA) and Matrigel invasion chambers (BD) were used to perform migration and invasion assays, respectively. Transfected cells were serum-starved for 24 hours and then 3×10^4^ B-CPAP cells in serum-free medium were seeded into the upper chamber. Complete medium was added to the bottom chamber. Cells were stained with 0.1% crystal violet for migration assays after 36 and 48 hours for invasion assays. Each assay was performed in triplicate. The number of cells from five fields in each well were counted by two investigators (HYL and DZ).

Clinical databases
------------------

The ONCOMINE datasets (<http://www.oncomine.org/>) were used to analyze the expression of *lncRNA H19* in various cancers against normal tissue as well as the correlated expression genes in thyroid cancer.[@b19-cmar-11-2059] The correlations between the expression levels of *lncRNA H19* and *Vimentin*, *ZEB2*, *Twist*, or *Snail2* in thyroid cancers were determined through analysis in the cBioPortal database (<http://www.cbioportal.org/index.do>).[@b20-cmar-11-2059] We analyzed thyroid carcinoma (TCGA, Provisional) and PTC (TCGA, Cell 2014) datasets. The expression levels of *lncRNA H19* in a series of cancers were analyzed by CCLE database (<https://portals.broadinstitute.org/ccle/home>), which is an online encyclopedia of a compilation of gene expression, chromosomal copy number, and massively parallel sequencing data from 947 human cancer cell lines.[@b21-cmar-11-2059]

Statistical analysis
--------------------

Statistical analysis was performed using the SPSS version 18.0. Data from three independent experiments were presented as the mean ± SD. Statistical analysis was performed using Mann--Whitney U test and Wilcoxon signed-rank test. The clinicopathological characteristics were analyzed using Pear-son's chi-squared test. Difference between multiple groups was analyzed by two-way ANOVA. For clinical data from ONCOMINE and cBioPortal datasets, Student's t-test was used, and two times of fold change with a *P*-value of \<0.01 was defined as clinically significant, Correlation coefficients between RNA levels were obtained through Spearman's rank correlation analysis as was described earlier.[@b22-cmar-11-2059] A value of *P*\<0.05 was considered as a statistically significant.

Ethical statement
=================

The study was approved by the ethics committee of the First Hospital of Shantou University Medical College. Patient consent was written informed consent, in compliance with the Declaration of Helsinki.

Results
=======

The expression level of *lncRNA H19* was significantly increased in PTC tissues
-------------------------------------------------------------------------------

*lncRNA H19* has been identified as an oncogenic gene in multiple cancer types and its elevated expression was tightly linked to tumorigenesis and cancer progression. ONCO-MINE analysis revealed that *lncRNA H19* expression was significantly higher in cancer than normal samples across a wide variety of datasets in different cancer types. A total of 220 different types of studies about *lncRNA H19* were collected in the ONCOMINE database ([Figure S1](#SD1-cmar-11-2059){ref-type="supplementary-material"}) in which 37 studies showed the increase of *lncRNA H19* expression and 22 studies showed a decrease. In addition, CCLE analysis demonstrated that the expression level of *lncRNA H19* in thyroid cancer cells ranked the eleventh highest in a variety of cancer cell lines tested ([Figure S2](#SD2-cmar-11-2059){ref-type="supplementary-material"}). Thus, we performed the qRT-PCR assay to detected PTC tissue samples and corresponding adjacent nontumorous tissues samples from 58 patients who were first diagnosed in our hospital. Our data showed that *lncRNA H19* expression was 2.417-fold higher (95% CI: 1.898--2.935) in PTC tissues than their paired paracancerous tissues ([Figure 1A](#f1-cmar-11-2059){ref-type="fig"}, *P*\<0.0001). These results implied that *lncRNA H19* may be distinctively expressed higher in thyroid cancer, suggesting it might play unique roles in the development of thyroid cancer.

Elevated *lncRNA H19* expression correlated with tumor burden of PTC
--------------------------------------------------------------------

To further investigate the correlation between *lncRNA H19* expression and clinicopathological features, qRT-PCR analyses of *lncRNA H19* were performed using samples from 58 PTC patients. When the 58 tumor tissues were stratified on clinical progression, we found that higher *lncRNA H19* expression is remarkably associated with increased tumor size ([Figure 1B](#f1-cmar-11-2059){ref-type="fig"}, *P*=0.0407). In addition, *lncRNA H19* expression levels were much higher in lymph node metastasis group than those in patients without lymph node metastasis ([Figure 1C](#f1-cmar-11-2059){ref-type="fig"}, *P*=0.0305). Moreover, high *lncRNA H19* expression was correlated with PTC patients of stage III/IV than those in patients with stage I/II ([Figure 1D](#f1-cmar-11-2059){ref-type="fig"}, *P*=0.0033). Consistently, when 58 PTC patients were divided into two group, *lncRNA H19*^High^ (\>median), and *lncRNA H19*^Low^ (\<median), our data also revealed that more patients in increased tumor size group (*P*=0.036), lymph node metastasis group (*P*=0.002), and higher stage group (*P*=0.004) correlated with *lncRNA H19*^High^ group ([Table 1](#t1-cmar-11-2059){ref-type="table"}). However, the level of *lncRNA H19* expression was not associated with age, gender, extrathyroidal extension status, pathological subtype, and whether combined with nodular goiter between these two groups ([Table 1](#t1-cmar-11-2059){ref-type="table"}). It was, therefore, postulated that the high *lncRNA H19* expression level was correlated with more malignant phenotypes with increased proliferation and potential of metastasis in PTC.

Higher expression of *lncRNA H19* correlated with elevated expression of mesenchymal phenotypes markers *Vimentin*, *ZEB2*, *Twist*, and *Snail2*
-------------------------------------------------------------------------------------------------------------------------------------------------

To explore the inherent properties of *lncRNA H19* and its potential mechanism in PTC, we used the ONCOMINE and cBioPortal databases to analyze the correlation of *lncRNA H19* in connection with other featured biomarkers in PTC. Interestingly, in ONCOMINE co-expression analysis, it was found that *lncRNA H19* expression was significantly correlated with the expression of *ZEB2*, a typical mesenchymal phenotypes marker ([Figure 2](#f2-cmar-11-2059){ref-type="fig"}, r=0.700). Moreover, gene correlation targeted analysis from TCGA database showed that in thyroid carcinoma, higher expression of *lncRNA H19* correlated with elevated mesenchymal biomarker *Vimentin* ([Figure 3A](#f3-cmar-11-2059){ref-type="fig"}, r=0.22, *P*\<0.001), *ZEB2* ([Figure 3C](#f3-cmar-11-2059){ref-type="fig"}, r=0.19, *P*\<0.001), *Twist* ([Figure 3E](#f3-cmar-11-2059){ref-type="fig"}, r=0.56, *P*\<0.001), and *Snail2* ([Figure 3G](#f3-cmar-11-2059){ref-type="fig"}, r=0.48, *P*\<0.001). Meanwhile, correlation analysis in PTC showed that elevated *lncRNA H19* correlated with increased expression of *Vimentin* ([Figure 3B](#f3-cmar-11-2059){ref-type="fig"}, r=0.20, *P*\<0.001), *ZEB2* ([Figure 3D](#f3-cmar-11-2059){ref-type="fig"}, r=0.23, *P*\<0.001), *Twist* ([Figure 3F](#f3-cmar-11-2059){ref-type="fig"}, r=0.57, *P*\<0.001), and *Snail2* ([Figure 3H](#f3-cmar-11-2059){ref-type="fig"}, r=0.50, *P*\<0.001). These results showed that the expression of *lncRNA H19* in PTC positively associated with mesenchymal phenotypes marker, which imply that *lncRNA H19* might play a distinct role in the processing of EMT and lead to more aggressive clinicopathological features of PTC.

*lncRNA H19* regulates mRNA and protein expression of EMT markers *E-Cadherin* and *Vimentin*
---------------------------------------------------------------------------------------------

Since the above data from the public database and clinical sample have shown that *H19* was correlated with EMT in PTC, we verified whether *lncRNA H19* was associated with typical EMT markers in PTC cell line B-CPAP. Suppression of *lncRNA H19* by siRNA caused a significant upregulation of epithelial marker *E-cadherin* expression at both the mRNA and protein levels, while that of *Vimentin*, a mesenchymal marker, decreased as compared to controls ([Figure 4A and B](#f4-cmar-11-2059){ref-type="fig"}). Two different siRNA sequences were used to silence *lncRNA H19* separately to exclude the possibility of nonspecific target. It was found that siH19-a and siH19-b effectively suppressed *lncRNA H19* and finally caused downregulated *Vimentin*, while upregulating *E-cadherin* both at mRNA and protein levels ([Figure 4A and B](#f4-cmar-11-2059){ref-type="fig"}). We chose siH19-b with better suppression effect on *lncRNA H19* for further experiments. Conversely, enforced expression of the exogenous *lncRNA H19* led to *E-cadherin mRNA* and protein downregulation and relative upregulation of *Vimentin* ([Figure 4C and D](#f4-cmar-11-2059){ref-type="fig"}). These results implied that *lncRNA H19* was able to mediate the process of EMT in PTC cells.

*lncRNA H19* promotes migration and invasion abilities of PTC cells
-------------------------------------------------------------------

To evaluate whether the expression of *lncRNA H19* regulates cellular function via inducing EMT, we performed gain-of-function and loss-of-function studies on B-CPAP cells. We first assessed the effect of *lncRNA H19* knockdown on cell motility via a wound healing assay. As displayed in [Figure 5A](#f5-cmar-11-2059){ref-type="fig"}, after culturing for 48 hours, the width of the scratch wound in siH19-b B-CPAP cells had reduced to 75% as compared to 0 hours, while the width of the scratch wound in control cells had reduced to 46% as compared to 0 hours ([Figure 5B](#f5-cmar-11-2059){ref-type="fig"}), indicating that loss of *lncRNA H19* expression inhibits cell motility. In contrast, when enforcing expression of the exogenous *lncRNA H19* in B-CPAP cells, the scratch wound width had healed to 26% as compared to 0 hours, dwarfing the 44% gap healed by control cells. This result suggests that *lncRNA H19* overexpression was capable of promoting the motility of B-CPAP cells ([Figure 5C](#f5-cmar-11-2059){ref-type="fig"}). We further investigated whether *lncRNA H19* influenced the migration and invasion abilities of B-CPAP cells via transwell migration and invasion assays. As shown in [Figure 5D](#f5-cmar-11-2059){ref-type="fig"}, the number of migrated cells transfected with siH19 was significantly lower (\~52%) than the number of migrated cells transfected with si-control ([Figure 5F](#f5-cmar-11-2059){ref-type="fig"}). Similarly, invasion assays showed that knocking down *lncRNA H19* via siRNAs resulted in fewer cells invading through the Matrigel-coated membrane ([Figure 5E and G](#f5-cmar-11-2059){ref-type="fig"}). Moreover, the ectopic expression of *lncRNA H19* in B-CPAP cells promoted cellular migration and invasion ([Figure 5D--G](#f5-cmar-11-2059){ref-type="fig"}). These results indicate that *lncRNA H19* enhances the migration and invasion abilities of PTC cells.

Discussion
==========

Thyroid cancer is the most common endocrine malignancy across the world.[@b1-cmar-11-2059] Its prevalence has been steadily increasing in the past few decades, primarily due to a remarkable increase in the incidence of PTC.[@b23-cmar-11-2059] Multiple patterns of genetic alteration, including BRAF mutations, RAS mutations, and RET/PTC rearrangements, have been identified to be critically involved in the tumorigenesis and progression of PTCs.[@b24-cmar-11-2059]--[@b26-cmar-11-2059] Targeting therapies toward these genetic alterations have led to a significant improvement in the therapeutic response and survival of patients with PTCs.[@b27-cmar-11-2059] Except for a series of protein-coding genetic alteration, a variety of noncoding transcripts have also been found to play essential roles in the development of a number of solid tumors.[@b28-cmar-11-2059]--[@b30-cmar-11-2059] However, up to now, the alteration in the noncoding transcript in PTCs remained under-investigated. It has been recognized in most studies that *lncRNA H19* overexpresses and contributes to tumorigenesis and progression of multiple cancer types, including gastric cancer, glioma, and head and neck squamous cell carcinoma.[@b10-cmar-11-2059],[@b11-cmar-11-2059],[@b31-cmar-11-2059] Nevertheless, it was found that *lncRNA H19* was under-expressed in intratumoral hepatocellular carcinoma (HCC) tissues, as compared to peritumoral tissues. Moreover, *lncRNA H19* could suppress the progression and metastasis of HCC.[@b32-cmar-11-2059] Lv et al also reported that downregulation of *lncRNA H19* and MiR-675 promotes migration and invasion of human HCC cells through AKT/GSK-3beta/Cdc25A signaling pathway.[@b33-cmar-11-2059]

*lncRNA H19* has been recognized to act as an oncogenic driver in a number of cancer types, such as gastric, breast, and lung cancers.[@b34-cmar-11-2059]--[@b36-cmar-11-2059] However, the specific function of *lncRNA H19* in thyroid cancer remains controversial. For example, Wang et al reported that *lncRNA H19* represses cell viability, and restrains migratory and invasive capabilities of thyroid cancer cells through downregulation of IRS-1.[@b37-cmar-11-2059] Lan et al demonstrated that inhibition of *lncRNA H19* promotes the proliferation and motility of PTC.[@b38-cmar-11-2059] On the contrary, Liu et al reported that increased *lncRNA H19* expression levels are associated with poor prognosis in thyroid cancer patients.[@b39-cmar-11-2059] Another study by Liu et al suggested that increased expression of *lncRNA H19* promoted growth, migration, and invasion in thyroid cancer, whereas *H19* knockdown impaired TC cell viability.[@b40-cmar-11-2059] Our analysis in the ONCOMINE database demonstrated that *lncRNA H19* expression was markedly higher in thyroid cancer than normal tissue samples. Particularly, the qRT-PCR assay of 58 PTCs and corresponding adjacent nontumorous tissues from our institution also showed that *lncRNA H19* expression was considerably higher in PTC tissues than paired paracancerous tissues. These findings consistently suggested that *lncRNA H19* distinctively was expressed higher in PTCs than normal counterparts. Notably, we found that higher *lncRNA H19* level was remarkably associated with larger tumor size, increased number of lymph node metastasis, as well as more advanced clinical stage, implying that higher *lncRNA H19* level is correlated to higher tumor burden of PTCs.

Notably, emerging evidences in recent years indicated that *lncRNA H19* acts as an important inducer of EMT.[@b12-cmar-11-2059],[@b36-cmar-11-2059],[@b41-cmar-11-2059] Matouk et al have reported that the role of the oncofetal *lncRNA H19* in tumor metastasis orchestrating the EMT-MET decision.[@b42-cmar-11-2059] Zhou et al reported that the *lncRNA H19* mediates breast cancer cell plasticity during EMT and MET plasticity by differentially sponging miR-200b/c and let-7b.[@b43-cmar-11-2059] However, whether *lncRNA H19* acts as an important inducer of EMT in papillary thyroid cancer remained unclear. Our analysis with ONCOMINE and cBioPortal databases, as well as TCGA datasets consistently demonstrated that *lncRNA H19* was positively associated with key EMT factors. It was found that higher expression of *lncRNA H19* was correlated to elevated expression of *Vimentin*, as well as critical EMT-associated transcription factors, including *ZEB2*, *Twist*, and *Snail2*.

Loss or decreased *E-cadherin* and increased *Vimentin* are universally regarded as the hallmark of the EMT process.[@b44-cmar-11-2059] In the present study, we first used the human PTC cell line B-CPAP to characterize the potential role of *lncRNA H19* and found that *lncRNA H19* was able to regulate mRNA and protein expression of EMT markers *E-Cadherin* and *Vimentin*, which suggested that *lncRNA H19* was pivotal driver of EMT in PTC cells. In addition, our study also showed that *lncRNA H19* promotes migration and invasion abilities of PTC cells. Shi et al reported that *lncRNA H19* predicts poor prognosis in patients with melanoma and regulates cell growth, invasion, migration, and EMT in melanoma cells.[@b12-cmar-11-2059] Liao et al reported that downregulation of *lncRNA H19* inhibits the migration and invasion of melanoma cells by inactivating the NF-κB and PI3K/Akt signaling pathways.[@b45-cmar-11-2059]

Conclusion
==========

In summary, the expression level of *lncRNA H19* was significantly higher in PTC tissues than paired paracancerous tissue or normal tissues. Elevated *lncRNA H19* expression was correlated with higher tumor burden of PTC. *lncRNA H19* regulates mRNA and protein expression of classic EMT markers *E-Cadherin* and *Vimentin* and promotes migration and invasion of PTC cells. *lncRNA H19* is a critical oncogenic driver in PTC, and targeted therapy against *lncRNA H19* might be a potential avenue, in conjunction with other conventional therapy, to increase the efficacy for patients with PTC.

Supplementary material
======================

###### 

Expression pattern of *H19* in different tumor types.

**Notes:** This figure shows the number of datasets with statistically significant RNA overexpression (red) or down-expression (blue) of the target gene (cancer vs. normal tissue). The *P*-value threshold is 0.01. The number in each cell represents the number of analyses that meet the threshold within those analysis and cancer types. The gene rank was analyzed by percentile of target gene in the top of all genes measured in each research. Cell color is determined by the best gene rank percentile for the analyses within the cell.

###### 

The RNA expression level of *H19* in thyroid cancer cells ranked eleventh highest in a variety of cancer cell lines from Cancer Cell Line Encyclopedia analysis (shown in red frame).

**Abbreviations:** RMA, return material authorization; CML, chronic myelocytic leukemia; AML, acute myelocytic leukemia; NSC, non-small cell.

###### 

Primers used in RT-PCR

  Gene           Forward primer                  Reverse primer
  -------------- ------------------------------- ------------------------------
                                                 
  *H19*          5′-TCTGAGAGATTCAAAGCCTCCAC-3′   5′-GTCTCCACAACTCCAACCAGTG-3′
  *E-cadherin*   5′-TGCCCAGAAAATGAAAAAGG-3′      5′-GTGTATGTGGCAATGCGTTC-3′
  *Vimentin*     5′-GAGAACTTTGCCGTTGAAGC-3′      5′-TCCAGCAGCTTCCTGTAGGT-3′
  *GAPDH*        5′-TGGACTCCACGACGTACTCAG-3′     5′-ACATGTTCCAATATGATTCCA-3′

**Abbreviation:** RT-PCR, real-time PCR.

###### 

Oligonucleotide sequences for siRNA constructs

  SiRNAs    sense (5′--3′)
  --------- -----------------------------
            
  siH19-a   5′-GCAGGACAUGACAUGGUCCTT-3′
  siH19-b   5′-CCAACAUCA AAGACACCAU-3′
  siNC      5′-UUCUCCGAACGUGUCACGU-3′

###### 

Antibodies used in this study

  Antibody       Catalog number   Company                                           Concentration rate   Species
  -------------- ---------------- ------------------------------------------------- -------------------- ---------
                                                                                                         
  *E-cadherin*   NCH-38           Dako Denmark A/S (Glostrup, Denmark)              1:3000               Rabbit
  *Vimentin*     D21H3            Cell Signaling Technology (Danvers, MA, USA)      1:2000               Rabbit
  GAPDH          sc-32233         Santa Cruz Biotechnology Inc. (Dallas, TX, USA)   1:3000               Mouse
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![Analysis of *lncRNA H19* expression in PTC patients according to qRT-PCR.\
**Notes:** (**A**) Relative expression of *H19* in cancer group and paracancerous group. (**B**) Relative expression of *H19* in T\<1.5 cm group and T≥1.5 cm group. (**C**) Relative expression of *H19* in non-metastasis group and lymph node metastasis group. (**D**) Relative expression of *H19* in stage I+II group and stage III+IV group (\**P*\<0.05, \*\**P*\<0.01, and \*\*\**P*\<0.001).\
**Abbreviations:** *lncRNA H19*, *long noncoding RNA H19*; PTC, papillary thyroid carcinoma; qRT-PCR, quantitative real-time PCR.](cmar-11-2059Fig1){#f1-cmar-11-2059}

![*H19* expression was significantly correlated with *ZEB2* expression in thyroid carcinoma (shown in red frame, from ONCOMINE correlation analysis).](cmar-11-2059Fig2){#f2-cmar-11-2059}

![Elevated *H19* expression correlated with higher expression of *Vimentin*, *ZEB2*, *Twist*, and *Snail2* in thyroid carcinoma.\
**Notes:** In the TCGA (the Cancer Genome Atlas) database, the Pearson's chi-squared test was performed to analyze the correlation of *H19* and some typical mesenchymal markers. (**A** and **B**) Gene correlation targeted analysis between *H19* and *Vimentin* in samples of (**A**) thyroid carcinoma or (**B**) PTC. (**C** and **D**) Gene correlation targeted analysis between *H19* and *ZEB2* in samples of (**C**) thyroid carcinoma or (**D**) PTC. (**E** and **F**) Gene correlation targeted analysis between *H19* and *Twist* in samples of (**E**) thyroid carcinoma or (**F**) PTC. (**G** and **H**) Gene correlation targeted analysis between *H19* and *Snail2* in samples of (**G**) thyroid carcinoma or (**H**) PTC.\
**Abbreviation:** PTC, human papillary thyroid carcinoma.](cmar-11-2059Fig3){#f3-cmar-11-2059}

![*H19* regulates expression of EMT marker *E-cadherin* and *Vimentin* in PTC cells.\
**Notes:** (**A** and **B**) Expression of *E-cadherin* and *Vimentin* in B-CPAP cells at protein and mRNA levels analyzed by (**A**) Western blot and (**B**) RT-PCR, respectively, when silencing *H19* by siH19-a and siH19-b. (**C** and **D**) Expression of *E-cadherin* and *Vimentin* in B-CPAP cells at protein and mRNA levels analyzed by (**C**) Western blot and (**D**) RT-PCR, respectively, when overexpressing *H19*. \**P*\<0.05 as compared to control groups.\
**Abbreviations:** EMT, epithelial-mesenchymal transition; PTC, papillary thyroid carcinoma; RT-PCR, real-time PCR.](cmar-11-2059Fig4){#f4-cmar-11-2059}

![*H19* knockdown in B-CPAP cells inhibits EMT while overexpression promotes EMT.\
**Notes:** (**A**--**C**) Wound healing assay showed the knockdown of *H19* inhibited the cellular motility of B-CPAP cells, while overexpression of *H19* enhanced such motility. (**A**) Representative pictures and (**B** and **C**) quantitative data of wound recovery after 48 hours cell culture. Each sample contained three wells. (**D**--**G**) Knockdown of *H19* decreased the cellular migration and invasion of B-CPAP cells; while overexpression of *H19* enhanced such motility. (**D**) Representative pictures of migration and (**E**) invasion, (**F**) quantitative data of migration, or (**G**) invasion assays. All experiments were performed at least thrice and data were statistically analyzed by two-way ANOVA. \**P*\<0.05 vs control. Error bars indicate SD.\
**Abbreviation:** EMT, epithelial-mesenchymal transition.](cmar-11-2059Fig5){#f5-cmar-11-2059}

###### 

Clinicopathological characteristics of 58 PTC patients according to *H19* expression

  Clinicopathological features   H19^High^ (\>median, n=29)   H19^Low^ (\<median, n=29)   *P*-value
  ------------------------------ ---------------------------- --------------------------- ---------------------------------------------------
                                                                                          
  Age                                                                                     0.115
   \<55 years                    17                           11                          
   ≥55 years                     12                           18                          
  Gender                                                                                  0.240
   Male                          6                            10                          
   Female                        23                           19                          
  Tumor size                                                                              0.036[a](#tfn1-cmar-11-2059){ref-type="table-fn"}
   ≤2 cm                         11                           19                          
   \>2 cm                        18                           10                          
  LN metastasis                                                                           0.002[a](#tfn1-cmar-11-2059){ref-type="table-fn"}
   Yes                           20                           8                           
   No                            9                            21                          
  Distance metastasis                                                                     1.000
   Yes                           27                           27                          
   No                            2                            2                           
  Clinical stage                                                                          0.004[a](#tfn1-cmar-11-2059){ref-type="table-fn"}
   I+II                          11                           22                          
   III+IV                        18                           7                           
  Extrathyroidal extension                                                                0.581
   Yes                           18                           20                          
   No                            11                           9                           
  Pathological subtype                                                                    0.730
   Classical                     25                           23                          
   Follicular                    4                            6                           
  Nodular goiter                                                                          
   Yes                           12                           11                          0.788
   No                            17                           18                          

**Notes:**

*P*-value\<0.05 was considered statistically significant.

**Abbreviations:** LN, lymph node; PTC, human papillary thyroid carcinoma.

[^1]: These authors contributed equally to this work
